F-star Alpha Ltd.
Bispecific antibodies with modified “constant” regions
This article was originally published in Start Up
Executive Summary
F-star Alpha Ltd., a UK-based start-up recently spun out of F-star Biotechnology Ltd., believes its method of making bispecific antibodies can produce powerful therapeutics that are also easy to manufacture. While the parent company says the spin-out is essentially a commercial vehicle meant to leverage the value of the parent company's technology platform, F-star Alpha is dedicated to developing bispecific antibodies and antibody fragments as cancer treatments.